In­nate Phar­ma woos Mond­her Mahjoubi away from As­traZeneca’s can­cer re­search ops to take the helm

France’s In­nate Phar­ma has re­cruit­ed As­traZeneca’s top can­cer spe­cial­ist to its helm. Mond­her Mahjoubi, who’s been the ther­a­peu­tic area head of on­col­o­gy, glob­al prod­uct and port­fo­lio strat­e­gy at As­traZeneca, is tak­ing over from Hervé Brail­ly, who be­comes chair­man of the su­per­vi­so­ry board.

Mahjoubi has been op­er­at­ing at As­traZeneca’s big Med­Im­mune sub­sidiary in Gaithers­burg, MD for the past three years, where it’s been hard at work on dur­val­um­ab, a PD-L1 check­point in­hibitor like­ly des­tined to be the fourth or fifth such im­muno-on­col­o­gy pro­gram to hit the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER